Endocrine · Full case

Type 2 Diabetes

NICE NG28 CKS 2026 ADA-EASD 📄 Patient leaflets

HbA1c ≥48 mmol/molDiagnostic threshold (×2 unless symptomatic)

42–47 mmol/molPre-diabetes — NHS DPP

<48 targetGeneral HbA1c target

<53 on SU/insulinHbA1c target if hypoglycaemia risk

eGFR 45 / 30Reduce / Stop metformin

BP <140/90Target in T2DM (<130/80 if ACR ≥70 or CKD)

DESMONDStructured education — offer at diagnosis

MR metformin + SGLT2iDual first-line (NG28, Feb 2026)

📋 Clinical Stem — Type 2 Diabetes Presentation

A patient presents with a raised HbA1c, symptoms of hyperglycaemia, or known T2DM for review

"The patient attends following an HbA1c of 56 mmol/mol identified at a routine health check. They are asymptomatic. They work as an HGV lorry driver and are worried about losing their licence. Their wife has Type 1 diabetes and uses insulin — they are terrified of injections."

T2DM affects over 4.4 million people in the UK with a mean 4–7 year delay from symptom onset to diagnosis. The same reasoning pathway applies whether this is new diagnosis, pre-diabetes counselling, or T2DM intensification. The two key questions are: (1) is this actually T2DM — or something else? (2) what is the safest, most effective, patient-centred treatment?

Scenario A — New diagnosis (SCA)HbA1c 56 at health check. HGV driver. Wife on insulin — injection fear. Wants to know about licence. Uncle had blindness from diabetes.

Scenario B — Poor controlKnown T2DM 3 years. HbA1c risen 52 to 68. On metformin 1g BD. "The tablets should be doing the job." Dietary denial. BMI 36.

Scenario C — Complications screenT2DM 5 years. Burning feet, visual blurring. Missed two annual reviews. BP 148/88. eGFR 55, ACR 14 mg/mmol. No foot exam documented.

Scenario D — Atypical / LADAAge 38, slim, BMI 22. HbA1c 62. Rapid failure of metformin. Personal Hashimoto's thyroiditis. Family history T1DM. GAD antibody?

Scenario E — Remission discussionT2DM 2 years. BMI 34. Has read about DiRECT trial. Wants to try 800 kcal/day diet to come off tablets. How to support and monitor?

Key variablesHbA1c level · eGFR · CVD/HF status · BMI · Occupation (HGV) · Drug history · Psychosocial context · Injection fear · DVLA implications

Your character

David Okafor, 52. Long-distance HGV lorry driver. You received a letter saying your blood test showed "high sugar" and have been asked to come in. You are not sure what diabetes means but your wife has Type 1 diabetes and relies on insulin — this terrifies you. Your uncle went blind from diabetes.

ICE — open only if asked

Ideas: You think diabetes means injections and that you will end up like your wife — disabled by insulin. You assume it might be reversible if you "just try harder."
Concerns: Losing your HGV licence would mean losing your job and identity. Also terrified of going blind like your uncle.
Expectations: Find out if you definitely have diabetes, whether you need injections, and exactly what happens to your licence.

"I got this letter about my blood sugar — I'm not really sure what it all means. My wife has diabetes and she's on injections. That's not going to happen to me, is it? And what about my licence? I can't lose my licence — it's my whole livelihood."

If the doctor explains your licence will be affected when it does not have to be, push back strongly: "So I'm going to lose my job? Are you sure about that?" Resist the management plan until: (1) licence rules explained accurately, (2) injections not needed confirmed, (3) specific follow-up date named. Volunteer uncle's blindness only if doctor asks about family history of diabetes complications.

Steps:

Step 1

History Taking — Open Question First · Symptoms · ICE · Psychosocial Context

▲collapse

Two parallel agendas in T2DM history: the clinical (is this really T2DM? are there complications? what is the CVD risk?) and the patient's (will I need injections? will I lose my licence? will I go blind?). Both must be explored before management. The history also identifies reversible contributors — treating these may dramatically improve glycaemic control.

🎓 SCA opener — use what you already know

"I can see from your blood test that your HbA1c — which is your blood sugar average over the last three months — came back at 56. Before I explain what that means, I'd like to hear from you first — what's been going through your mind since you got that letter?"

Acknowledge the HbA1c result — it is in the notes. Then open the floor. The patient's narrative reveals their fear (injections, licence, blindness) and hidden agenda in one response.

1A — Open question first, then targeted history

Question to ask	Why it matters clinically	Changes what?
🟢 OPEN QUESTION — always start here"Tell me what has been going through your mind since you got that letter about your blood sugar result — and how are you feeling about it?"	Surfaces the hidden agenda immediately. Patients with new T2DM almost always have fears (injections, blindness, amputation, driving) they will not volunteer unless given space. One open question often replaces four targeted ones. The patient who says "my wife uses insulin and I'm terrified" has told you the entire ICE in one sentence.In SCA: licence and injection fears will be volunteered here — respond directly before moving to data gathering. Finishing by 6–7 min requires this efficiency.	Reveals hidden agendaICE in one responseShapes whole consultation
Symptoms of hyperglycaemia?"Have you noticed increased thirst, passing more urine, tiredness, or blurred vision?"	Classic triad: polyuria, polydipsia, weight loss. Many T2DM patients at diagnosis are asymptomatic — unlike T1DM which is more acute. Significant symptoms raise urgency and suggest higher glucose. Blurred vision = osmotic lens swelling (acute) vs retinopathy (chronic) — distinguish by timing.Symptomatic + single HbA1c ≥48 = diagnose without second test. Asymptomatic = two separate results required.	Severity + urgencySecond test needed?
Microvascular symptoms?"Any burning, tingling or numbness in your feet? Any changes to your vision recently? Any difficulties with erections?"	Neuropathy, retinopathy, nephropathy — may already be present at diagnosis (mean 7-year diagnostic delay). Neuropathy affects QoL and foot risk. ED is a sensitive marker of vascular disease and significant psychosocial burden — often the most important finding. Asking normalises it.ED is 3× more common in T2DM. Identifies vascular disease early. Opens psychosocial door.	Complications at diagnosisEye / foot screening
Occupation and driving?"What does your work involve? How important is your driving to you — and what type of licence do you hold?"	DVLA Group 2 (HGV/bus) licence holders with T2DM face specific rules. On diet/non-hypoglycaemic tablets only: usually no notification required. On sulfonylurea or insulin: must notify DVLA; annual review; glucose strip-test before and 2-hourly on journeys. Licence fear must be addressed factually — it drives David's entire consultation agenda.Failure to explore this = patient disengages from the whole management plan.	Drug choice (avoid SU)Central agenda
Diet and lifestyle?"Can you describe a typical day of eating — and how much physical activity do you get?"	Diet is the most powerful first-line intervention — HbA1c reduction up to 20 mmol/mol achievable with sustained change. DiRECT trial: 800 kcal/day for 12 weeks induced remission in 46% at 1 year. Occupational diet (HGV drivers: motorway services, irregular meals) shapes realistic advice.Standard dietary advice fails lorry drivers — explore occupational reality before advising.	Lifestyle planPractical feasibility
Family history of diabetes and complications?"Does anyone in your family have diabetes? Have any of them had problems — with their eyes, kidneys, or feet?"	Strong genetic component in T2DM. Family complications (uncle's blindness in David's case) are both a motivator for adherence and a marker for fear that must be named and addressed. Naming the uncle's blindness in the management plan = high-quality shared decision-making.Do not just collect this data — use it. "We can prevent what happened to your uncle."	Motivational framingRisk stratification
Smoking, alcohol, reversible causes?"Do you smoke? How much alcohol do you drink? Any recent illness, significant stress, or new medications?"	Smoking doubles CVD risk in T2DM — the most modifiable risk factor for mortality. Alcohol: hidden calorie source, hypoglycaemia risk with sulfonylureas, heavy use = pancreatogenic diabetes or neuropathy mimicking diabetic neuropathy. Steroids, thiazides, antipsychotics = secondary hyperglycaemia worth identifying.	CVD riskSecondary causes

1B — Red flags: act before continuing history

🚨

Red Flags in T2DM — act before continuing

Red flag	Why dangerous	Action
DKA: vomiting + ketones ≥3 + glucose >11 (esp. on SGLT2i — euglycaemic DKA)	Life-threatening. Metformin in DKA = lactic acidosis. SGLT2i DKA: glucose may appear near-normal — high clinical suspicion needed.	999 immediately
HHS: glucose >30 + confusion + profound dehydration + no significant ketones	Mortality 15–20%. Gradual onset over days. IV fluids needed cautiously. VTE risk extremely high.	999 immediately
FAST positive symptoms in a diabetic patient	T2DM carries 2–4× stroke risk. Silent MI common (neuropathy blunts pain). Thrombolysis window 4.5 hours.	999 — FAST protocol
Slim patient + unintentional weight loss + rapid oral failure — possible LADA	Misdiagnosed as T2DM in up to 10%. GAD antibody positive. Sulfonylureas accelerate beta-cell burnout.	GAD antibody + diabetologist same week
Active foot ulcer, deep infection, or acute Charcot joint	50% of UK amputations in diabetic patients. Osteomyelitis can develop in days. IV antibiotics often needed.	MDT foot clinic same day
Sudden vision loss in a known diabetic patient	Vitreous haemorrhage or retinal detachment. Background retinopathy may already be present at diagnosis.	Same-day ophthalmology

🛡️

Safeguarding Considerations — Consider in Every T2DM Consultation

Diabetes can be both a cause and a marker of harm. Uncontrolled T2DM — especially where medication is withheld, appointments are missed, or deterioration is rapid — may have a safeguarding component. Always consider the wider context beyond the glucose result.

🏠 Domestic Abuse / Coercive Control

Chronic fear and stress → sustained sympathetic activation → worsened glycaemic control and BP
Partner attending and speaking over patient = controlling behaviour signal; offer to see patient alone
Medication being withheld or sabotaged as a form of control
Ask sensitively: "How are things at home? Do you feel safe?"
Use DASH tool if concerned. Refer to IDVA / MARAC if high risk.

👴 Older Adults / Carer Concern

Carer administering incorrect doses or withholding insulin / tablets
Financial abuse → inability to afford food, medication, or heating → food insecurity worsens T2DM
Unexplained deterioration in self-care, weight loss, or missed clinic appointments
Frail elderly with hypoglycaemia and no one to call = serious, avoidable harm
Refer to Adult Safeguarding if concern identified; document explicitly

🧒 Children in the Household

Parent with severe hypoglycaemia or DKA who is sole carer — who is looking after the children?
Parental T2DM in context of substance misuse or mental health crisis may overlap with child protection concerns
Food poverty affecting whole family — children at nutritional risk alongside parent
Document; consider referral to children's services if child welfare at risk

💊 Self-Harm / Medication Risk

Insulin and sulfonylureas can be used in deliberate self-harm or self-poisoning
If prescribing to a patient at risk: consider pack size; alert co-prescribers; safety-net explicitly
Diabetes distress and depression are strongly associated — PHQ-9 at every diagnosis and review
Screen for disordered eating (diabulimia — deliberate insulin omission for weight control)

If a safeguarding concern is identified: You do not need certainty — a concern is sufficient to act. Document clearly in the records. Discuss with your safeguarding lead. Refer to the appropriate agency (IDVA, Adult Safeguarding, Children's Services). Follow your organisation's policy. Do not let the HbA1c management agenda override immediate safety.

1C — PMH · FH · Drug history · Social history

🧬 PMH / FH — changes management

Factor	Why it matters	Management impact
Hypertension	Most common comorbidity; synergistic CVD risk. BP target <140/90 in T2DM; tighten to <130/80 with CKD or ACR ≥70 (NG203)	ACEi/ARB first-line — dual cardio-renal protection; intensify earlier
CKD / eGFR reduction	Metformin: reduce at eGFR <45, stop at <30; SGLT2i restricted; affects DOAC choice for AF	eGFR-guided prescribing; ACEi/ARB renoprotective
Established CVD / HF	Changes Step 2 drug priority: SGLT2i has proven mortality benefit in both CVD and HFrEF	Empagliflozin/dapagliflozin add-on after metformin regardless of HbA1c
Obesity (BMI ≥35)	GLP-1 RA or SGLT2i preferred — both cause significant weight loss vs SU/insulin which cause weight gain	Semaglutide (GLP-1 RA): 10–15% body weight loss; remission potential
LADA risk factors	Slim, age 30–50, personal autoimmune history, rapid oral failure — consider GAD antibody	If LADA: reclassify, refer to diabetologist; insulin will be needed
Pancreatitis history	Pancreatogenic (Type 3c) DM — exocrine failure; GLP-1 RA contraindicated; insulin dependent earlier	Refer; PERT; specialist-led insulin
Family history T1DM	Raises LADA suspicion; GAD antibody testing warranted if atypical features	GAD, C-peptide — refer if positive
Diabetes complications (FH)	Uncle's blindness = motivational resource; drives adherence; must be named in plan	"We can prevent what happened to your uncle" — use this

💊 Drug history — interactions and safety

Drug	Interaction / issue	Action
Corticosteroids	Steroid-induced hyperglycaemia — can precipitate T2DM or dramatically worsen control	Monitor glucose carefully; may need insulin during steroid course
Thiazide diuretics	Worsen glycaemic control; increase glucose; relevant bleeding-risk factor if on anticoagulation	Consider switching to indapamide SR; review necessity
Atypical antipsychotics	Olanzapine, clozapine: significant weight gain + glucose dysregulation	More frequent monitoring; lifestyle support; consider switch if possible
NSAIDs (e.g. ibuprofen)	Worsen renal function; interact with ACEi/ARB/diuretic ("triple whammy" = AKI risk)	STOP before starting ACEi/ARB + diuretic; switch to paracetamol
Statins (high-dose)	Atorvastatin 80mg: modest increase in T2DM risk — but CVD benefit overwhelmingly outweighs	Do not withhold; counsel; monitor HbA1c
Metformin + contrast	Contrast nephropathy risk — hold metformin 48h before contrast procedures	Sick day rules card — essential at every prescription
Sulfonylurea + alcohol	Prolonged hypoglycaemia — alcohol inhibits hepatic glucose release; very dangerous for HGV drivers	Counsel explicitly; carry glucose; MedicAlert; DVLA briefing

1D — ICE: Ideas · Concerns · Expectations

💭 Ideas

"What does the word diabetes mean to you? When you got that letter, what picture did that bring to mind — was it your wife's situation you thought of?"

Most patients with a T1DM family member assume T2DM = the same trajectory. Correcting the T1 vs T2 distinction early and explicitly is the single most powerful intervention in this consultation.

😟 Concerns

"I want to address the three things you mentioned — the injections, your licence, and what happened to your uncle's eyes. Let me go through each one specifically."

Three layered concerns: (1) injections/wife's disability, (2) HGV licence loss — immediate occupational threat, (3) uncle's blindness — named complication fear. All three must be addressed specifically, not with generic reassurance.

🎯 Expectations

"What were you hoping we could sort out today — and what would make this appointment feel like it had been worthwhile?"

David expects: diagnosis confirmed, injections not needed confirmed, licence rules clarified. Address expectation BEFORE management plan — not as an afterthought. This is an explicit SCA scoring criterion.

1E — Psychosocial context: the person living with T2DM

🚛 Occupation and livelihood

HGV driving is David's income and identity. Accurate DVLA information is existential. Wrong information (telling David he loses his licence on metformin) destroys trust immediately.

"With the tablet I'm recommending, your licence does not change — the DVLA rules only apply when drugs that can cause low blood sugar are used."

💉 Injection fear (wife's T1DM)

David's mental model is his wife's T1DM experience. Explicitly correcting T1 vs T2 and naming that injections are not the next step removes the primary barrier to engagement.

"Type 2 is completely different from what your wife has — your pancreas still works. Injections are not what we're discussing today."

👁️ Uncle's blindness

Named, specific fear. Use as motivational frame AND justification for NDESP referral. "We can prevent what happened to your uncle" is the highest-quality shared decision-making phrase in this consultation.

"We're setting up annual eye screening today so we catch any changes before they cause problems."

🛣️ Occupational diet

Motorway services, irregular hours, long sits. Standard dietary advice fails lorry drivers completely. Explore the reality before advising — a dietitian with occupational context is far more effective than a leaflet.

"Advice for someone on the road all day is different — what does a realistic day of eating actually look like for you?"

🧠 Diabetes distress

45% of T2DM patients experience significant diabetes distress — distinct from depression but equally impairs glycaemic control. PHQ-9 at diagnosis and annually.

"Beyond the practical questions — how are you feeling emotionally about this diagnosis?"

👨‍👩‍👧 Family dynamics

Wife may be David's primary — and most misleading — source of information. Invite her to DESMOND together. This reframes both their understanding and reduces household anxiety.

"Would your wife like to come to the education session with you? It might help both of you."

🎓 SCA Checkpoint — Step 1 Relating to OthersGlobal Skills

Say / Do

Reference the HbA1c result from the notes before speaking — never ask for information you already have
Use the open question first — let David name injections and licence without prompting
Explore all three ICE domains — ideas (T1DM assumption), concerns (licence + uncle), expectations (no injections + licence clarity)
Pick up the uncle's blindness detail if volunteered — name it in the management plan later
Finish data gathering by 6–7 minutes — open question achieves this efficiency

Deductions

Asking for results already in the referral letter — Domain 1 (Global Skills) deduction
Moving straight to management before ICE is explored
Not asking about occupation — misses the entire DVLA agenda
Collecting uncle blindness data but not using it in the plan
Rigid tick-box questioning — prevents emotional cues from surfacing

"I can see from your blood test that your HbA1c came back at 56. Before I explain what that means, I'd like to hear from you — what's been going through your mind since that letter arrived?"

🔴 Red

Asks for results already in notes · No open Q · ICE not explored · Occupation not asked · Goes straight to prescribing

🟠 Amber

Open Q attempted but then rigid tick-box · ICE at start only · Licence mentioned but not explored · Uncle blindness not used in plan

🟢 Green

Notes used first · Open Q yields ICE spontaneously · All three ICE domains explored · Uncle named and used in shared decision-making · Completes history by 6–7 min

Step 2

Triage Engine — Emergency · Urgent · Routine

▼expand

T2DM red flags are often missed because the diagnosis feels routine. DKA can occur in T2DM (especially on SGLT2i). HHS carries 20% mortality. Atypical features may indicate LADA, MODY, or secondary diabetes — lifetime misdiagnosis risks are significant. Always triage before assuming T2DM is straightforward.

Emergency

🚨 Call 999

Immediate — do not wait

DKAVomiting + glucose >11 + ketones ≥3 + Kussmaul breathing. Rare in T2DM but can occur — especially on SGLT2i.
HHSGlucose >30 + profound dehydration + confusion + no significant ketones. Mortality 20%. Gradual onset.
Silent MI / FAST positiveAF + T2DM = 2–4× stroke risk. Silent MI common (neuropathy blunts pain). Any FAST symptoms = 999 without delay.
Sudden vision lossVitreous haemorrhage or retinal detachment — diabetic emergency. Same-day ophthalmology minimum.
Active foot sepsis / gangreneNecrotising infection + ischaemia = limb-threatening. MDT foot clinic same day; IV antibiotics.

Urgent — same/next day

⚠ Act this week

Face-to-face urgently

HbA1c >86 mmol/mol at first presentationVery high glucose — risk of osmotic symptoms, infections, visual change. Consider dual therapy from outset.
Significant unintentional weight loss + hyperglycaemiaLADA / T1DM / pancreatic cancer masquerading as T2DM. Do NOT label as T2DM without GAD antibody.
New foot ulcer or Charcot jointNeuropathic / ischaemic foot emergency. Podiatry + MDT foot clinic within 24h.
Rapid oral agent failure (<6 months)Suggests LADA / beta-cell burnout / pancreatogenic DM — specialist input needed urgently.
Any retinal change on screeningBackground retinopathy → ophthalmology. Proliferative retinopathy → urgent ophthalmology same week.

Routine — planned

✓ Planned pathway

NICE NG28 structured care

HbA1c 48–85, asymptomaticConfirm with second test (asymptomatic). Full baseline investigations. Lifestyle + metformin pathway.
Pre-diabetes HbA1c 42–47NHS Diabetes Prevention Programme referral. Lifestyle intervention. Annual HbA1c monitoring.
Known T2DM, stable reviewAnnual review pathway: HbA1c + eGFR + ACR + lipids + BP + foot + eyes + medication review.
Intensification neededHbA1c above target on current therapy — step up treatment in planned consultation with psychosocial context.

🎓 SCA Checkpoint — Step 2 TasksGlobal Skills

Say / Do

Name red flags aloud — "I want to make sure there are no signs of anything needing urgent attention"
Screen for DKA/HHS: vomiting, confusion, dehydration?
Consider LADA if slim, young, rapid deterioration — ask about autoimmune history
Screen for active foot problems and visual change at every diabetes presentation

Deductions

Treating all elevated HbA1c as routine T2DM without considering alternatives
Not considering LADA in a slim patient with rapid oral agent failure
Missing euglycaemic DKA in a patient on SGLT2i who appears well
Not asking about vision, feet, or symptoms before prescribing

🔴 Red

No red flag screen · Diagnoses T2DM in a slim patient without considering LADA · Misses DKA on SGLT2i · No foot or eye check

🟠 Amber

Most red flags considered · LADA not actively screened · DKA on SGLT2i not known · Foot/vision mentioned but not explored

🟢 Green

Active red flag screen · LADA considered if features present · SGLT2i DKA risk known · Foot + vision screening recommended at diagnosis

Step 3

Do I Need This Examination?

▼expand

Every examination finding must link to a management decision. In T2DM, the NICE-mandated annual review examination forms the baseline at diagnosis. Do not examine without explaining why to the patient — explanation is itself a domain 3 opportunity.

Examination	Why it matters in T2DM	What finding changes management	Changes management?
BP — both arms, 5 min rest	Target <140/90 in T2DM (<130/80 if CKD/ACR ≥70). BP discrepancy >15 mmHg between arms suggests peripheral vascular disease.Each 10 mmHg SBP reduction reduces MI risk by 22% in T2DM.	≥140/90 on ×2 (or ≥130/80 if CKD/ACR≥70) → start ACEi/ARB. Discrepancy >15 mmHg → investigate PVD.	YES — always
BMI + waist circumference	Central obesity (waist >102cm men, >88cm women) = insulin resistance. BMI ≥35 → SGLT2i or GLP-1 RA preferred (weight loss benefit). DiRECT: 15 kg loss → remission in 46%.Waist circumference predicts T2DM risk independently of BMI.	BMI ≥35 → prioritise GLP-1 RA/SGLT2i; assess for remission pathway	YES — drug choice
Foot exam (mandatory at diagnosis)	NICE mandates foot exam at diagnosis and annually. 10g monofilament at 4 plantar sites. Absent pulses = PVD. Callus, ulcer, deformity, Charcot = high-risk.50% of UK amputations are in T2DM patients. Neuropathy may pre-exist diagnosis by years.	Loss of sensation / absent pulses → podiatry. Active ulcer → MDT same day.	YES — urgency + referral
Cardiovascular exam (heart sounds, JVP, pulses)	Target organ damage baseline. T2DM doubles CVD risk. Signs of HFrEF change Step 2 drug choice — SGLT2i proven to reduce HF mortality (EMPEROR-Reduced, DAPA-HF).	Signs of CVD/HFrEF → SGLT2i/dapagliflozin priority regardless of HbA1c level	YES — drug priority
Fundoscopy / NDESP referral	Retinopathy may already be present at diagnosis. NICE: refer ALL newly diagnosed T2DM patients to NDESP immediately. Uncle's blindness in this case = direct motivational frame for this referral.Background retinopathy progresses silently — annual photography catches it before vision is affected.	Any retinopathy → ophthalmology. Proliferative → urgent same week.	YES — mandatory
Acanthosis nigricans / Cushingoid features	Acanthosis nigricans (velvety dark skin, neck/axillae) = severe insulin resistance. Cushingoid features (striae, moon face, central fat, bruising) = secondary diabetes — treat the underlying cause first, not just the glucose.	Cushingoid features → dexamethasone suppression test → endocrinology	YES — secondary cause

🎓 SCA Checkpoint — Step 3 Tasks

Say / Do — explain before you examine

"I would like to check your blood pressure, your weight, and your feet — these are the three most important checks we do for everyone newly diagnosed with diabetes."
Link foot exam to patient's fear: "Your uncle had problems with his eyes — we are going to check your feet and set up eye screening today so we can catch any changes very early."
Explain every finding: "Your blood pressure is higher than the ideal target for someone with diabetes — that's important because it changes how well we protect your heart and kidneys."

Deductions

Not examining the feet at a first T2DM appointment — mandatory at diagnosis
Not referring to diabetic eye screening at diagnosis
Examining without explaining rationale — missed domain 3 opportunity
Not checking BP in both arms at first presentation

🔴 Red

No foot exam · No BP · Eye screening not mentioned · Examination not explained

🟠 Amber

BP + weight done · Foot exam omitted or incomplete · Eye screening not referred · Rationale partial

🟢 Green

BP both arms · BMI/waist · Complete foot exam with monofilament · CVS exam · Eye screening referral explained · Each finding linked to management decision

Step 4

Do I Need This Investigation?

▼expand

Every investigation should answer a specific clinical question. NICE mandates a minimum dataset at diagnosis and at each annual review. The result must change management — if it will not, question whether the test is needed. Always explain the test and its purpose to the patient.

Investigation	Clinical question it answers	What result changes management?
HbA1c (confirm + baseline)	Diagnoses T2DM; sets baseline for treatment targets. Asymptomatic = two separate results required. HbA1c unreliable in haemoglobinopathy, haemolytic anaemia, recent transfusion — use fasting glucose instead.	42–47 = pre-diabetes. 48–85 = T2DM: lifestyle + metformin. >86 = consider dual therapy from outset. Symptomatic + single result = diagnose without second test.
eGFR + U&E + creatinine	Baseline renal function before prescribing. Metformin dosing depends on eGFR. CKD is present at diagnosis in ~25% of T2DM patients. K⁺ affects choice of ACEi/ARB safety.	eGFR <45: reduce metformin. eGFR <30: STOP metformin. K⁺ >5.5: avoid ACEi/ARB. AKI = hold metformin immediately (sick day rules).
Urine albumin:creatinine ratio (ACR)	Early nephropathy marker. ACR ≥3 mg/mmol = microalbuminuria. Changes BP target and drug choice. Tighter BP target required if ACR elevated.	ACR ≥3 → start ACEi/ARB (renoprotective) even without hypertension. ACR ≥30 → intensify BP to <130/80. ACR ≥70 → tightest BP targets; nephrology referral considered.
Lipid profile (TC, HDL, LDL, TG)	QRISK3 calculation requires lipids. T2DM patients aged >40 (or QRISK3 ≥10%): atorvastatin 20mg recommended for primary prevention (NICE NG28/NG238). LDL drives statin intensity decision.	LDL >2.6 despite lifestyle: add/intensify statin. TG >10 mmol/L: pancreatitis risk — fibrate. Non-fasting TG >4.5: recheck fasting.
Liver function tests (LFTs)	Baseline for metformin and statin. NAFLD (now MASLD) present in up to 70% of T2DM — hepatic insulin resistance. AST:ALT >2:1 = alcoholic disease. Elevated ALT affects statin safety threshold.	ALT >3× ULN: caution with statin; hepatology referral. NAFLD diagnosis changes lifestyle management priority.
Thyroid function (TSH)	Hypothyroidism causes weight gain, dyslipidaemia, and worsened glucose control. Common comorbidity especially in women. NICE recommends checking at T2DM diagnosis.	Hypothyroid: treat first — glycaemic and lipid control may improve significantly. Hyperthyroid: raises glucose; treat.
GAD antibody + C-peptide (selected cases)	If LADA suspected: slim, young (<50), personal/FH autoimmune disease, rapid oral agent failure, no obesity. C-peptide reflects residual beta-cell function. GAD positive = autoimmune.	GAD positive: reclassify as LADA/T1DM. C-peptide <0.2 nmol/L: insulin-dependent. Refer to diabetologist — do not start sulfonylurea.
ECG	Baseline cardiovascular assessment in newly diagnosed T2DM. T2DM carries 2–4× MI risk. Silent ischaemia common. LVH changes BP management targets.	LVH: intensify BP control. AF: anticoagulation + rate control decision. Silent ischaemia: cardiology referral.

🎓 SCA Checkpoint — Step 4 Tasks

Explain to patient

"I am going to request a set of blood tests — the main ones check how your kidneys are working, your cholesterol levels, your thyroid, and your liver, because these all affect which tablets are safest for you."
"We will also check your urine for very early signs of any kidney stress — this test is called an ACR and it is part of the routine diabetes check."
Never request investigations without explaining purpose — wastes a domain 3 opportunity

Deductions

Prescribing metformin without confirming eGFR — risk of lactic acidosis in renal failure
Not ordering ACR — misses nephropathy that changes drug choice
Not requesting TFTs — hypothyroidism worsens control
Diagnosing T2DM on one HbA1c without symptoms — must confirm with second test

🔴 Red

Prescribes metformin without eGFR · No ACR · No lipids · No TSH · Diagnoses on single HbA1c (asymptomatic)

🟠 Amber

HbA1c + eGFR ordered · ACR or lipids missed · TSH not considered · Rationale given for some tests only

🟢 Green

Full NICE minimum dataset ordered · Result thresholds known and verbally shared · Each test linked to management decision · GAD considered if LADA features · Tests explained in lay language

Step 5

Reaching a Diagnosis — T2DM Classification · Lay Language · DDx · DVLA

▼expand

T2DM is a clinical diagnosis supported by investigation. The differential is broader than it first appears. Always consider alternative diagnoses before labelling someone with T2DM for life — misdiagnosis carries significant consequences.

5A — Differential diagnosis in lay language + clinical discriminators

Type 2 Diabetes Mellitus ✓ Most likely

Lay: "raised sugar from lifestyle + genetic factors"

HbA1c ≥48 on two occasions (asymptomatic). Age >40, overweight, sedentary, FH T2DM. Gradual onset. Insulin resistance + progressive beta-cell failure. Lifestyle + metformin = first-line.

Pre-Diabetes (NDH)

Lay: "high sugar on the way — but reversible"

HbA1c 42–47. Fasting glucose 6.1–6.9. No symptoms. 50% progress to T2DM within 10 years without intervention. NHS DPP referral. Metformin not routinely offered.

LADA (Latent Autoimmune Diabetes)

Lay: "slow-burning Type 1"

Slim, age 30–50, autoimmune history, rapid oral failure. GAD antibody positive. Will need insulin. Sulfonylureas accelerate beta-cell loss — avoid. Refer to diabetologist urgently.

MODY (Maturity-Onset Diabetes of Youth)

Lay: "inherited mild diabetes"

Age <25, slim, dominant FH 3 generations, no autoantibodies, no obesity. MODY2: no treatment. MODY3: sulfonylurea-sensitive. Genetic testing via specialist.

Type 1 DM (Late-Onset)

Lay: "insulin-dependent diabetes in adulthood"

Rapid onset, significant weight loss, high glucose, ketosis. No obesity. GAD/IA-2 positive. Needs insulin immediately — labelling as T2DM and giving metformin alone risks DKA.

Secondary / Pancreatogenic DM

Lay: "diabetes caused by another condition"

Pancreatitis history, steroid use, Cushing's, acromegaly. GLP-1 RA contraindicated in pancreatic disease. Treat underlying cause first. Insulin often required early.

5B — How to communicate the diagnosis (SCA)

💬 Lay diagnosis explanation — chunk and check

"Your blood test result shows that the average level of sugar in your blood has been running higher than it should be for a while. We call this Type 2 diabetes. The important thing to understand is that Type 2 diabetes is very different from what your wife has — your wife has Type 1, which is an autoimmune condition where injections are needed from the start. Type 2 works very differently. At this stage, for most people, we manage it with lifestyle changes and one tablet. Injections are not something we are talking about today. Does that make sense so far — what does that bring up for you?"

🚛 DVLA explanation — for Group 2 drivers

"Because you drive professionally, the rules around diabetes and driving are important — so let me be specific. With Type 2 diabetes managed by diet and exercise alone, or by tablets that do not lower your blood sugar too far, the DVLA does not require you to notify them and you can continue to drive your HGV. The tablet I am going to recommend today — metformin — falls into that category. It does not cause low blood sugar on its own. So your licence is not at risk at this stage."

If sulfonylurea or insulin were ever needed later: you would then need to notify the DVLA, and there are specific blood glucose check rules before and during drives. But that is not where we are today — and we will do everything we can to avoid that stage."

🎓 SCA Checkpoint — Step 5 TasksRelating to Others

Say / Do

Explain T1DM vs T2DM distinction clearly and specifically — "very different from what your wife has"
Name that injections are NOT required at this stage — early, specific, unprompted
State DVLA rules accurately for Group 2 (HGV) drivers
Use chunk-and-check: pause after each piece — "Does that make sense so far?"
Link uncle's blindness to prevention: "We can prevent what happened to your uncle"

Deductions

Telling David he will lose his licence when metformin-only does NOT require notification
Using jargon (HbA1c, hyperglycaemia, glycaemic) without explanation
Saying "injections might be needed soon" without evidence — catastrophises unnecessarily
Not using chunk-and-check — information flooding without confirming understanding

🔴 Red

Wrong DVLA information · Jargon · Does not distinguish T1/T2 · Does not address injection fear · No chunk-and-check

🟠 Amber

Diagnosis communicated but not in lay terms · Injection fear partially addressed · DVLA mentioned but rules incomplete · No chunk-and-check

🟢 Green

T1 vs T2 distinction explicit · Injections not needed stated unprompted · DVLA rules accurate and specific · Lay language throughout · Chunk-and-check used · Uncle blindness linked to prevention

Step 6

If Referral Is Needed — What the GP Does Before & During

▼expand

Most T2DM is managed in primary care. But several scenarios require specialist input — and delaying referral in these cases carries significant patient harm. Know which T2DM presentations need expert guidance and with what urgency.

Scenario	Urgency	What GP does before/during referral	What GP must NOT do
LADA suspected (slim, autoimmune, rapid oral failure)	Same week	Request GAD antibody + C-peptide immediately. Do not start sulfonylurea. Continue metformin cautiously. Refer diabetologist for reclassification and insulin planning.	Do NOT start SU — accelerates beta-cell burnout. Do NOT delay referral while awaiting results.
Diabetic eye screening (NDESP) — all new T2DM	At diagnosis	Refer to NDESP immediately at diagnosis. Tell the patient: "Annual retinal photography — we catch changes before they cause vision problems. This is how we prevent what happened to your uncle."	Do NOT wait until next appointment to refer. Do NOT omit — the uncle's blindness makes this especially significant in this consultation.
DESMOND (structured self-management education)	Within 3 months	Refer all newly diagnosed T2DM. Explain: "Group education session proven to improve diabetes control and wellbeing. Your wife could come too — it might help both of you." Document referral made.	Do NOT omit — NICE-mandated. Omission is a Tasks deduction in SCA.
Active foot ulcer / Charcot joint	Same day	MDT foot clinic same day. Offloading. Wound care. Vascular assessment. IV antibiotics if infection present. Document urgency of referral clearly.	Do NOT manage active foot ulcer in primary care alone. Do NOT wait for routine podiatry appointment.
HbA1c >75 despite triple oral therapy	Within 4 weeks	Confirm medication adherence first. Check eGFR (renal function affects options). Discuss insulin with patient. Refer diabetologist for structured insulin education programme.	Do NOT initiate insulin without structured education. Do NOT delay if adherence is confirmed.
ACR ≥70 or rapidly declining eGFR	Routine nephrology	Start ACEi/ARB if not already prescribed (renoprotective). Optimise BP. Continue SGLT2i dapagliflozin for CKD benefit (licensed to eGFR ≥25 for this indication). Refer nephrology.	Do NOT stop SGLT2i at eGFR <45 if prescribed for CKD benefit — check indication-specific threshold in SPC.

🎓 SCA Checkpoint — Step 6 Tasks

Referrals to make at diagnosis

NDESP (diabetic eye screening) — mention by name at every new diagnosis
DESMOND (structured self-management education) — mandatory NICE recommendation
Podiatry if high-risk foot identified on examination
Dietitian — especially for lorry driver with occupational dietary barriers
NHS DPP referral if pre-diabetes (HbA1c 42–47)

Deductions

Not offering DESMOND — NICE-mandated; omission = Tasks deduction
Not referring to NDESP at diagnosis — mandatory; uncle's blindness makes this highly relevant
Not considering dietitian for a patient with significant occupational dietary constraints
Delaying diabetologist referral when LADA features are present

🔴 Red

No DESMOND offered · No eye screening referral · No foot clinic if high-risk · Diabetologist not considered despite LADA features

🟠 Amber

DESMOND mentioned but not actively referred · Eye screening mentioned not booked · Dietitian not suggested despite occupational context

🟢 Green

DESMOND referral made and explained to patient · NDESP booked at diagnosis · Dietitian offered · Podiatry if indicated · Diabetologist if atypical features

Step 7

Management — Expectation · Drug Selector · Drug Reference · Psychosocial · Follow-Up · Safety-Netting

▲collapse

7A — Address expectation BEFORE the management plan

🎯

SCA exam-critical: validate expectation first — then negotiate plan

Validate the fear

David has two specific fears: injections (wife's experience) and licence loss. Both are rational. Acknowledge them explicitly by name before launching into any management plan.

"Before I go through the plan, I want to come back to the two things you mentioned at the start — the injections and your licence. Can I address both of those directly first, and then we can go through everything together?"

Explain with evidence

Distinguish T2DM from T1DM. Explain that the tablet recommended today does not cause hypoglycaemia — therefore the DVLA rules do not apply in the same way.

"The tablet I am recommending — metformin — works very differently from insulin. It cannot cause your blood sugar to go too low on its own. That means it falls into the DVLA category where you can continue your HGV licence without notification."

Negotiate the plan

Offer specific lifestyle change agreed with patient, drug counselling on metformin, and name the referrals. Use uncle's blindness as a motivational frame for monitoring.

"Your uncle lost his sight — I want to make sure that does not happen to you. We can prevent that by keeping your blood sugar and blood pressure controlled. Let me show you how we do that, step by step, starting today."

7B — Why treatment matters: goals tailored to this patient

Treatment goals

HbA1c <48 mmol/molBP <140/90 (<130/80 if CKD/ACR≥70) Protect kidneys (ACEi/ARB if ACR ≥3)Prevent complications Weight loss 5–15%T2DM remission if ≥15kg lost DESMOND + structured educationSafe driving (no hypo risk drugs first)

Motivational language

"I know your uncle lost his sight to diabetes. I want you to know that what happened to him does not have to happen to you. We caught this early. With the right plan, we can keep your sugar levels and blood pressure well controlled — and we check your eyes every year so we would catch any changes before they cause problems."

"Some people with Type 2 diabetes who lose enough weight actually get their blood sugar back to normal without any tablets — we call that remission. It is not guaranteed, but it is possible — and we can support you to try."

7C — Non-medication management: mechanism + evidence + tailored advice

Never give generic lifestyle advice. Each intervention below has a specific mechanism, a quantified effect on HbA1c or CVD risk, and a measurable outcome. Present each as a real treatment — and tailor it to what this patient's life actually looks like. One change agreed today beats five changes ignored. For David: motorway services, long driving hours, and sedentary work mean standard advice fails. Explore his reality before prescribing lifestyle change.

🥗

Low-GI / Mediterranean Diet

Target: reduce refined carbs; 800 kcal/day for remission

Mechanism

↓ Postprandial glucose spikes → ↓ HbA1c. ↑ Fibre → slows gut absorption. Mediterranean pattern: ↑ unsaturated fats + polyphenols → ↓ insulin resistance + endothelial inflammation.

Evidence

PREDIMED: Mediterranean diet reduced T2DM incidence by 30%. DiRECT: 800 kcal/day total diet replacement → 46% remission at 1 year with ≥15 kg loss. LOOK AHEAD: intensive lifestyle → sustained HbA1c improvement.

Tailored — HGV driver

Motorway services reality: pre-pack nuts, low-sugar protein bars, fruit in cab. Plan service-station choices in advance. Avoid meal skipping → reactive overeating. Dietitian referral with occupational context.

↓ HbA1c 10–20 mmol/mol (diet alone)

⚖️

Weight Loss

Target: ≥5% body weight; ≥15 kg for remission

Mechanism

↓ Visceral fat → ↓ hepatic fat → restored hepatic insulin sensitivity. ↓ Adipokine-driven inflammation. ↓ RAAS activation → ↓ BP + proteinuria. Improves beta-cell function directly.

Evidence

DiRECT trial: ≥15 kg loss → 86% remission. NHS Total Diet Replacement (800 kcal/day, 12 weeks) — available on NHS. Each 1 kg lost: ~1 mmHg BP reduction + incremental HbA1c improvement.

Tailored framing

"Losing 5 kg is like taking a blood pressure tablet." For David: even modest weight loss protects his kidneys and eyes — both of which matter directly to his uncle's story and his driving licence.

↓ HbA1c 5–15 mmol/mol; remission if ≥15 kg

🏃

Physical Activity

Target: 150 min/week moderate + resistance 2×

Mechanism

Muscle contraction → GLUT4 translocation (insulin-independent glucose uptake during exercise). ↓ Peripheral vascular resistance via endothelial NO → ↓ BP. ↑ Mitochondrial density → ↓ insulin resistance long-term.

Evidence

Meta-analysis: 150 min/week moderate activity → HbA1c ↓ 5–10 mmol/mol. Resistance training adds independently. Even 10-min walks after meals blunt postprandial glucose spikes (RCT evidence).

Tailored — HGV driver

Walk at delivery drops instead of waiting in cab. Resistance bands behind seat. Short walks after meal breaks. Evening walks after shift. "Every 10 minutes matters — you don't need a gym."

↓ HbA1c 5–10 mmol/mol (dose-dependent)

🍺

Alcohol Reduction

Target: ≤14 units/week, spread over ≥3 days

Mechanism

Chronic alcohol → ↑ cortisol + RAAS → Na⁺ retention + ↑ BP. Impairs hepatic glucose release (hypoglycaemia risk on SU/insulin). Binge drinking → acute glucose dysregulation. Liver damage → impaired glycogen storage.

Evidence

Each drink above guideline level: ↑ HbA1c. Alcohol binge + SU or insulin = prolonged hypoglycaemia — dangerous for HGV drivers (DVLA rules). Alcohol worsens peripheral neuropathy directly.

Tailored — HGV + driving

Alcohol + sulfonylurea = prolonged hypo — especially dangerous behind the wheel. Brief intervention: AUDIT-C. DrinkCoach app referral. "Alcohol on a driving day with this tablet could be very dangerous."

↓ HbA1c + ↓ BP + reduces hypo risk on SU

🧂

Salt Reduction

Target: <6g/day (2.4g sodium)

Mechanism

↓ Plasma volume → ↓ cardiac output → ↓ BP. In T2DM: salt restriction additively protective for kidneys alongside ACEi/ARB — reduces intraglomerular pressure independently. Particularly effective in CKD + T2DM.

Evidence

RCT evidence: ↓ SBP 4–5 mmHg with 6g/day target. In proteinuric T2DM nephropathy: salt restriction enhances ACEi efficacy and reduces ACR. Caution: potassium-based salt substitutes (LoSalt) — avoid in CKD or on ACEi/ARB (hyperkalaemia risk).

Practical — lorry driver

Most salt is in processed food (sandwiches, crisps, ready meals) — the default for HGV drivers. "Don't add salt" is not enough: identify specific high-salt foods in his daily diet and offer alternatives.

↓ SBP 4–5 mmHg + renal protection

🚭

Smoking Cessation

Target: complete cessation

Mechanism

Nicotine → acute sympathomimetic surge per cigarette → BP spikes. Long-term: endothelial damage + ↑ vascular stiffness + accelerated atherosclerosis. In T2DM: smoking doubles the risk of nephropathy and neuropathy progression independently of glycaemic control.

Evidence

Smoking + T2DM: all-cause mortality risk multiplied. CVD event risk ↓ 50% within 1 year of cessation. Renal protection: cessation slows ACR progression. NICE: offer NRT + pharmacotherapy + behavioural support at every consultation.

Practical

QUIT service referral + NRT patch. CO breath test at every review — objective feedback motivates. Varenicline (most effective) or combination NRT. "Your kidneys and eyes will thank you more than anything else we discuss today."

↓ CVD risk 50% within 1 yr; slows nephropathy

7D — Prescribing Guide: what to start, in what order, and why

⚠ Guideline update — NICE NG28, 18 February 2026

Metformin monotherapy is no longer “Step 1 for all”. If glucose-lowering medication is needed, NICE now recommends modified-release metformin AND an SGLT2 inhibitor as dual first-line therapy for the majority of adults — even with no comorbidity at all (introduced stepwise: metformin first to check tolerability, then add the SGLT2i; SGLT2i only if frailty does not place them at risk of volume depletion/hypotension). Metformin contraindicated or not tolerated → SGLT2i monotherapy, or a DPP-4i if frailty makes an SGLT2i unsafe. The pathway then branches by phenotype rather than climbing one queue: established ASCVD → triple first-line (MR metformin + SGLT2i + s/c semaglutide up to 1mg weekly); heart failure → SGLT2i; CKD → SGLT2i (eGFR 20–30: dapagliflozin or empagliflozin with a DPP-4i); obesity or early-onset (<40 years) → earlier GLP-1 RA or tirzepatide; frailty → relax the target, avoid/use caution with SGLT2i, fewest medicines at lowest effective dose. Before any SGLT2i: check previous DKA, dehydration/volume-depletion risk and very-low-carbohydrate or ketogenic diet, do not start during intercurrent illness, follow MHRA ketone-monitoring advice, and give written sick-day rules with a restart plan. The step numbering below is retained for teaching the reasoning, but read “Step 1” as dual MR metformin + SGLT2i and Step 2 as the phenotype branch. Existing patients stable at target on metformin alone do not need changing today — but run a targeted register review, because most will now qualify for SGLT2i addition. See the Type 2 Diabetes protocol for the rebuilt pathway.

Three decisions, in this order, every time: (1) Is this the right patient for this drug — confirm eGFR, contraindications, and cardiovascular/renal status before any prescription. (2) Which part of the NICE NG28 (Feb 2026) pathway applies — dual first-line therapy, or a phenotype branch? (3) Within that, which agent fits this patient's phenotype, comorbidities, occupation, and preferences? For David: MR metformin plus an SGLT2 inhibitor is now first-line — but eGFR must be confirmed, the SGLT2i DKA/frailty pre-checks done, DVLA implications addressed, and injection fear resolved before any injectable discussion.

Before prescribing anything — confirm these checks first

🔬 Confirm eGFR before metformin

Metformin is contraindicated if eGFR <30 (lactic acidosis risk). Reduce dose if eGFR 30–45. Review eGFR at baseline and annually — or 6-monthly if declining. SGLT2i also eGFR-restricted: glycaemic benefit lost below eGFR 45; renal/CV benefit continues to eGFR 20–25 (dapagliflozin CKD licence).

"Before I start any tablets I need to check your kidney function — a blood test will tell me which medicines are safe for you."

🚛 Clarify DVLA status before prescribing

For Group 2 drivers (HGV/bus): the drug choice directly determines whether DVLA notification is required. Metformin, SGLT2i, DPP-4i, GLP-1 RA: no notification. Sulfonylurea: must notify DVLA + monitoring obligations. Insulin: must notify + annual review. Address this before the patient leaves — wrong information here can destroy trust and engagement.

"The good news is: the tablet I'm planning to start doesn't cause blood sugar to drop — so the DVLA rules don't apply at this stage."

💬 Address injection fear before Step 2

For David, injection fear must be resolved before any conversation about GLP-1 RA or insulin. Introduce Step 2 options without injections first (SGLT2i, DPP-4i). If GLP-1 RA is the clinically preferred option, address the fear directly and explicitly — distinguish from insulin, quantify the injection frequency, show a device if possible.

"The next tablet I'd consider doesn't involve injections at all — let me explain how it works."

Only once eGFR confirmed + DVLA implications addressed + patient fears explored → proceed to drug selection below

Step-by-step prescribing order — NICE NG28 / NG17

Step 1

DUAL — all T2DM

START: MR metformin 500mg OD → titrate to 1–2g daily, AND add an SGLT2 inhibitor

NG28 (Feb 2026): initiate modified-release metformin in preference to standard-release (standard-release only if tablets must be crushed or a liquid is needed). Start 500mg OD with food, increase by 500mg every 1–2 weeks as tolerated. Confirm eGFR ≥30 before starting. Then add dapagliflozin 10mg or empagliflozin 10mg OD — dual therapy is now first-line even with no comorbidity, unless contraindicated or frailty makes an SGLT2i unsafe (then metformin alone; if metformin is the problem, SGLT2i alone, or a DPP-4i if frail).

WHY this pair first

Neither drug causes hypoglycaemia — critical for HGV drivers, and neither requires DVLA notification. Metformin: extensive safety data (UKPDS 10-year CV benefit), weight neutral or modest loss, cheapest agent, HbA1c ↓10–20 mmol/mol. SGLT2i: cardiovascular, renal and mortality benefit that is independent of glucose lowering — which is why NICE stopped waiting for HbA1c to “justify” it, and why generic dapagliflozin made it affordable at scale.

→ Pre-SGLT2i checks: previous DKA, dehydration risk, ketogenic diet; not during acute illness; sick-day rules given. Review HbA1c at 3 months and intensify by phenotype if above the agreed target

Step 2A

CVD · HF · CKD · Obesity

ADD: SGLT2 inhibitor — empagliflozin or dapagliflozin

Empagliflozin 10mg OD (CVD/HF) or dapagliflozin 10mg OD (CKD — licensed to eGFR 25 for renal benefit). Add to metformin. Sick day rules mandatory — hold if unwell, vomiting, or fasting (euglycaemic DKA risk). Genital hygiene counselling (thrush risk).

WHY SGLT2i first at Step 2

Proven CV mortality and HF hospitalisation benefit independent of HbA1c (EMPA-REG OUTCOME, DAPA-HF, EMPEROR-Reduced). Slows eGFR decline in CKD (DAPA-CKD). Modest weight loss (2–3 kg). No hypoglycaemia — safe for HGV. No DVLA notification. Use even if HbA1c is at target if CVD/HF/CKD present.

→ Check eGFR 2–4 weeks after starting. Review HbA1c at 3 months.

Step 2B

Obesity · High HbA1c

ADD: GLP-1 receptor agonist — semaglutide or liraglutide

Semaglutide (Ozempic) 0.25mg SC weekly → titrate to 1mg. Or liraglutide 0.6mg OD → 1.2mg. Subcutaneous injection — not insulin, no hypoglycaemia risk. Address injection fear explicitly before prescribing. Check pancreatitis history — contraindicated.

WHY GLP-1 RA for obesity / high HbA1c

Strongest HbA1c lowering of oral/injectable agents (10–20 mmol/mol reduction). Weight loss 5–15% with semaglutide (SUSTAIN trial). CV benefit in established CVD (LEADER, SUSTAIN-6). No hypoglycaemia — no DVLA notification. For David: address "not injections like my wife" explicitly — this is weekly, not daily, and not insulin.

→ Titrate dose at 4 weeks. Review HbA1c at 3 months. Stop if <1% (11 mmol/mol) HbA1c reduction at 6 months.

Step 2C

HGV-safe · No CV indication

ADD: DPP-4 inhibitor — sitagliptin 100mg OD

Sitagliptin 100mg OD (dose-reduce to 50mg if eGFR 30–50; 25mg if eGFR <30). Or alogliptin, saxagliptin (avoid saxagliptin/alogliptin in HF — possible hospitalisation signal). Well-tolerated, weight-neutral, once-daily. No hypoglycaemia. No DVLA notification.

WHY DPP-4i when SGLT2i/GLP-1 RA not suitable

Glucose-dependent mechanism: stimulates insulin only when glucose is elevated — zero hypoglycaemia risk. Ideal for HGV drivers, elderly patients, and those with eGFR restrictions on SGLT2i. Moderate HbA1c lowering (5–10 mmol/mol). No DVLA notification for any driver. Well tolerated in CKD with dose adjustment.

→ Review HbA1c at 3 months. If still above target, consider adding SGLT2i if not already given.

Step 2D

Last-choice Step 2

ADD: Sulfonylurea — gliclazide MR 30–120mg OD

Gliclazide MR preferred SU (lower hypo risk than glibenclamide). Start 30mg OD with breakfast. Titrate to 120mg OD. Warn about hypoglycaemia at every visit. Weight gain 1–2 kg. For HGV: must notify DVLA, glucose monitoring before and during every drive, no driving if glucose <5.

WHY SU is last-choice at Step 2

Hypoglycaemia risk is the major limiting factor — especially for HGV, elderly, and those living alone. Weight gain worsens insulin resistance. No CV or renal benefit beyond glucose lowering. DVLA Group 2 notification mandatory. Good HbA1c lowering (10–15 mmol/mol) but at the cost of these risks. Use when all other Step 2 options are contraindicated or unsuitable.

→ ⛔ HGV drivers: DVLA notification mandatory before driving continues. Sick day rules: stop if not eating.

Step 3–4

Triple / Insulin

INTENSIFY: Triple therapy → insulin — specialist involvement

Triple: MR metformin + SGLT2i + GLP-1 RA (or DPP-4i) — note that in established ASCVD, NG28 (Feb 2026) makes MR metformin + SGLT2i + s/c semaglutide (up to 1mg weekly) the FIRST-LINE regimen, not a later rung. If HbA1c >75 on dual or triple therapy: consider insulin. Start with basal insulin (insulin glargine or detemir once daily). Refer to diabetology if LADA suspected, rapid deterioration, or if HbA1c >86 at presentation. DESMOND referral at diagnosis.

WHY this order and when to refer

Combination therapy targets multiple pathophysiological defects simultaneously. Basal insulin as first insulin (once daily) minimises injection burden and hypoglycaemia risk. For HGV drivers: insulin = must notify DVLA + annual licence review + strip testing before and during drives. Address injection fear at this stage — the conversation has shifted from "maybe" to "now." Specialist input for all insulin starts.

→ ⛔ HGV + insulin: DVLA notification mandatory. Annual Group 2 licence review required. No driving within 45 min of hypoglycaemia.

Within the step — choose the right drug for this patient's phenotype

Step 2 drug selection by clinical scenario

Scenario	Choose	Why
HFrEF (EF <40%)	Empagliflozin	Mortality + HF hospitalisation benefit. First priority regardless of HbA1c.
Established CVD	SGLT2i or GLP-1 RA	CV mortality benefit in both classes. Choose based on weight, eGFR, and preference.
CKD (eGFR 25–60)	Dapagliflozin	Slows eGFR decline. Licensed for CKD benefit to eGFR 25 (DAPA-CKD).
BMI ≥35 / high HbA1c	Semaglutide	10–15% weight loss. Strongest HbA1c lowering. CV benefit in CVD.
HGV / hypo risk	Sitagliptin (DPP-4i)	No hypo. No DVLA. Glucose-dependent mechanism. Safe in CKD with dose adjust.
GI intolerance to metformin	Metformin SR	Modified-release significantly reduces GI side effects. Take with evening meal.
LADA suspected	Refer — no SU	SU accelerates beta-cell loss in LADA. GAD antibody + C-peptide first. Insulin likely.

DVLA Group 2 (HGV/bus) — drug decision matrix

Drug class	DVLA Group 2	Monitoring required
Metformin	No notification	None beyond standard annual review
SGLT2i	No notification	Sick day rules mandatory
GLP-1 RA	No notification	None — no hypo risk as monotherapy
DPP-4i	No notification	None — glucose-dependent mechanism
Sulfonylurea	Notify DVLA	BG before every drive. 2-hourly on journeys. No drive if BG <5.
Insulin	Notify DVLA	Annual licence review. BG before and 2-hourly. 45 min wait post-hypo.

⛔ Document DVLA counselling in notes at every prescription change · Wrong DVLA advice to a HGV driver = serious medico-legal risk

⛔ Absolute prescribing rules — never broken: (1) Confirm eGFR before starting metformin or SGLT2i — do not prescribe blind. (2) SGLT2i + unwell / vomiting / fasting = hold (euglycaemic DKA risk — sick day rules card mandatory). (3) SU or insulin + HGV = DVLA notification before patient drives again — document in notes. (4) GLP-1 RA + pancreatitis history = contraindicated — always ask. (5) LADA suspected = do not start SU — refer urgently, check GAD antibody.

⚙ Interactive Medication Chooser — tick the patient profile, options re-tier live against NICE / BNF

A live, topic-scoped version of the standalone Medication Chooser. The static selector and reference cards below are unchanged.

7E — Medication selection tool — choose patient characteristics for tailored drug recommendations

7F — Drug reference cards

Metformin

Glucophage · Metformin SR (slow release preferred)

✓ First-line — with an SGLT2i (dual)

Step 1 500mg BD → 1g BD (over 4 weeks)

✓ Use for

All T2DM first-line, in the MR formulation — and now paired with an SGLT2 inhibitor (NG28, Feb 2026) regardless of weight, age, ethnicity or comorbidity

No hypoglycaemia risk as monotherapy — safe for HGV drivers without DVLA notification

Pre-diabetes + BMI ≥35 + high progression risk (NICE consideration)

✗ Avoid / caution

eGFR <30 — risk of lactic acidosis: STOP

eGFR 30–44 — reduce dose; reassess regularly

Contrast medium within 48h — hold metformin (sick day rule)

Acute illness with dehydration — hold until eating/drinking normally

⚠ Side effects

GI upset (nausea, diarrhoea) — most common reason for stopping; SR formulation reduces this significantly — try before switching class

Vitamin B12 deficiency with long-term use — check B12 if neuropathy develops

Lactic acidosis — very rare; mainly in renal failure or shock

• Monitor

eGFR + U&E at baseline, 3–6 months, then annually

HbA1c at 3 months post-initiation, then 6-monthly until stable

Vitamin B12 annually after 4 years of use

💬 Counselling phrase

"This tablet helps your body use its own insulin more efficiently — it doesn't cause low blood sugar on its own. Take it with food to reduce any stomach upset. The first few weeks can cause some nausea — that usually settles, especially with the slow-release version."

DVLA: metformin as monotherapy does not require DVLA notification and does not restrict HGV driving. No hypoglycaemia risk. This is the key point for David — address it explicitly when prescribing.

SGLT2 Inhibitor

Empagliflozin · Dapagliflozin · Canagliflozin

✓ Priority Step 2

Step 2 Empagliflozin 10mg OD

✓ Prioritise when

Established CVD — mortality benefit (EMPA-REG OUTCOME trial)

Heart failure HFrEF — reduces hospitalisation independently of glucose control

CKD — slows progression (dapagliflozin licensed for CKD eGFR ≥25)

Obesity — causes 2–4 kg weight loss; modest BP reduction

✗ Avoid if

eGFR <45 — glucose-lowering effect lost; stop (CKD indication threshold differs — check SPC)

Recurrent UTI / genital mycotic infections — glycosuria promotes fungal growth

Volume depletion / loop diuretics — AKI risk; sick day rules essential

Hold 3 days before surgery / prolonged fast — euglycaemic DKA risk

⚠ Side effects

Genital thrush — most common (~10%); hygiene advice; antifungal if needed

Euglycaemic DKA — glucose may be near-normal; ketones raised; intercurrent illness risk

Fournier gangrene (rare) — perineal pain + erythema = urgent referral

• Monitor

eGFR + U&E before starting and at 2–4 weeks

Ketones if unwell — sick day rules card mandatory at every prescription

💬 Counselling phrase

"This tablet makes your kidneys remove excess sugar in your urine. Keep the genital area clean and dry — some people get thrush. Drink plenty of water. If you feel very unwell, check your ketones and seek help even if your blood sugar seems normal."

SGLT2i as monotherapy or with metformin: no hypoglycaemia — safe for HGV drivers without DVLA notification. However euglycaemic DKA = life-threatening; sick day rules briefing is mandatory at every prescription.

GLP-1 Receptor Agonist

Semaglutide (Ozempic) · Liraglutide · Dulaglutide

✓ Priority Step 2

Step 2–3 Semaglutide 0.25mg → 1mg weekly SC

✓ Prioritise when

BMI ≥35 — superior weight loss (10–15% body weight with semaglutide)

Established CVD — cardiovascular benefit (LEADER, SUSTAIN trials)

HbA1c very high at baseline — superior glucose lowering

T2DM remission goal — dual therapy from outset if HbA1c >86

✗ Avoid if

Personal/FH medullary thyroid cancer or MEN2

Pancreatitis history — GLP-1 RA associated with acute pancreatitis risk

Gastroparesis — GLP-1 slows gastric emptying; may worsen

Severe renal impairment — limited data at eGFR <30

⚠ Side effects

Nausea, vomiting, diarrhoea — commonest; usually transient; slow dose-titration reduces

Acute pancreatitis (rare) — abdominal pain → stop and investigate

Gallstones — rapid weight loss increases biliary sludge risk

• Monitor

HbA1c + weight at 3 months — stop if no ≥1% HbA1c reduction or ≥3% weight loss at 6 months (NICE criterion)

Amylase/lipase if abdominal symptoms develop

💬 Counselling phrase

"This is a weekly injection under the skin — but I want to be very clear: it is completely different from insulin. It works by mimicking a natural gut hormone that helps you feel fuller. It does not cause low blood sugar on its own. Some people find this comparison helpful: think of it as a biological appetite signal, not a sugar-lowering drug."

GLP-1 RA: injections ≠ insulin — critical for David. No hypoglycaemia risk as monotherapy. Does not require DVLA notification. Frame it correctly: "This is very different from what your wife uses."

Sulfonylurea (SU)

Gliclazide MR · Glipizide

⚠ Use with caution

Step 2 Gliclazide MR 30mg OD → 120mg OD

✓ Consider when

Second-line add-on to metformin if SGLT2i/GLP-1 RA not suitable or not funded

Rapid HbA1c lowering needed — potent glucose-lowering effect

Cost: cheapest add-on option

✗ Avoid or extreme caution

HGV / Group 2 licence drivers — MUST notify DVLA; strip-test before every drive and 2-hourly on journeys >2h; do not drive if glucose <5 mmol/L; wait 45 min after hypo before driving

eGFR <30 — drug accumulation; prolonged hypoglycaemia risk

Elderly — greater hypo risk; use lowest dose with monitoring

Irregular meals (HGV drivers) — very high hypo risk; counsel extensively

⚠ Side effects

Hypoglycaemia — most significant; prolonged with alcohol use; fatal if unrecognised while driving

Weight gain 1–3 kg (adds to T2DM burden)

• Monitor

HbA1c 3-monthly; eGFR annually (dose-adjust with renal decline)

Blood glucose self-monitoring mandatory for HGV drivers on SU — DVLA requirement

💬 Counselling phrase

"This tablet directly stimulates your pancreas to release insulin. It can cause low blood sugar if you skip meals or drink alcohol. Always carry glucose tablets or a sugary drink. If you drive professionally, there are specific rules we need to go through — your licence may be affected."

For David (HGV driver): sulfonylurea triggers mandatory DVLA notification, blood glucose monitoring requirements, and strict driving restrictions. Avoid unless no alternative — prefer metformin ± SGLT2i or DPP-4i to protect his HGV licence.

DPP-4 Inhibitor (Gliptin)

Sitagliptin · Alogliptin · Saxagliptin

✓ Recommended

Step 2 Sitagliptin 100mg OD

✓ Consider when

SGLT2i/SU not suitable — weight-neutral, well-tolerated option

Hypoglycaemia risk — glucose-dependent mechanism; no hypo on its own

Moderate CKD — dose-adjust sitagliptin for eGFR; can use down to eGFR 15

HGV-safe: no hypoglycaemia risk; no DVLA notification required as monotherapy

⚠ Caution

Saxagliptin: avoid in heart failure (HF hospitalisation signal — SAVOR trial)

Less HbA1c lowering than SU or SGLT2i — not suitable as sole agent for high HbA1c

Rare: acute pancreatitis; bullous pemphigoid (sitagliptin)

• Monitor

HbA1c at 3–6 months; eGFR annually (dose-adjust if eGFR falls)

No DVLA notification required — HGV-safe as monotherapy

💬 Counselling phrase

"This tablet enhances your body's own insulin system — but only when your blood sugar is actually raised. That means it cannot cause low blood sugar on its own. It is weight-neutral and very well-tolerated by most people."

Gliptins: no hypoglycaemia, no DVLA notification, HGV-safe. Weight-neutral — less potent than SGLT2i for CVD/HF but useful when SGLT2i contraindicated or not tolerated.

Insulin

Glargine (Lantus) · Detemir · Degludec · Isophane (NPH)

Step 4+ — specialist initiation

Step 4+ Basal OD — specialist-initiated

✓ Consider when

HbA1c consistently >75 despite triple oral therapy

Rapid beta-cell decline — rising HbA1c despite intensification

Severe hyperglycaemia at presentation with osmotic symptoms

Pregnancy — insulin is only agent with robust safety data in T2DM

⚠ HGV drivers on insulin — DVLA Group 2 rules

Must notify DVLA — licence reviewed annually

Must strip-test glucose before every drive and 2-hourly on journeys >2h

Must not drive if glucose <5 mmol/L

Must wait 45 min after hypoglycaemia before driving

DVLA may grant Group 2 licence with insulin if stable, no recent hypos, and monitoring compliance confirmed

⚠ Side effects

Hypoglycaemia — requires full education programme including Hypo Awareness training

Weight gain 2–6 kg

Injection site lipohypertrophy — rotate sites; affects absorption

💬 Counselling phrase

"Insulin is something we add when the tablets are no longer doing enough — and reaching that stage is not a failure on your part. We will train you fully with a specialist nurse. And importantly: insulin does not automatically end your HGV licence. The DVLA can grant a Group 2 licence for people on insulin who meet their monitoring criteria."

For David: insulin does NOT automatically end his HGV licence. DVLA can grant Group 2 licence with insulin with annual review and monitoring compliance. Providing accurate information prevents catastrophisation and disengagement from the plan.

7G — Psychosocial context: integrate into the plan

💛

Psychosocial Factors — Shape Every Management Decision

🚛

Occupational impact (HGV licence)

David's job is his identity and income. Accurate DVLA information prevents catastrophisation. Metformin-only: no notification. SU/insulin: notification + monitoring rules. Document the counselling.

"With the tablet I am recommending, your licence situation does not change. I will document this conversation in your notes."

💉

Injection fear (wife's T1DM)

David's mental model of diabetes is his wife's T1DM. Explicitly correcting the T1 vs T2 distinction and naming that injections are not the next step reduces fear-driven disengagement.

"What your wife has is a different type — it is autoimmune. Type 2 works differently. We are not talking about injections at all today."

👁️

Uncle's blindness (complication fear)

Named, specific fear. Use it as motivational frame: "We can prevent what happened to your uncle." Refer to NDESP immediately. Annual screening detects changes before vision is affected.

"Your uncle's blindness — I want to make sure that does not happen to you. That is exactly why we are setting up annual eye screening today."

🛣️

Occupational diet (motorway services)

Standard dietary advice fails lorry drivers. Long hours, irregular stops, motorway food = practical barriers. Explore the reality before advising. Dietitian referral with occupational context is more effective than generic leaflets.

"I know dietary advice is harder when you are on the road all day. Can we talk about what realistic options look like for you?"

🧠

Diabetes distress

45% of T2DM patients experience significant diabetes distress — distinct from depression but equally impairs glycaemic control. PHQ-9 at diagnosis and annual review. NHS Talking Therapies / DSN emotional support available.

"Getting a diagnosis like this can feel like a lot. How are you feeling emotionally about all of this, beyond the practical questions?"

👨‍👩‍👧

Family dynamics (wife's T1DM)

Wife may be David's primary information source — her experience may be misleading. Inviting the wife to attend DESMOND with David can reframe both their understanding of T2DM vs T1DM.

"Would your wife be willing to come along to the education session with you? It might be helpful for both of you."

7H — Follow-up timeline

Diagnosis visit — today

HbA1c confirmed (2nd test if asymptomatic) · eGFR + U&E + ACR + lipids + LFTs + TSH + ECG · BP (both arms) + weight + foot exam · NDESP referral booked · DESMOND referral made · Sick day rules card given · DVLA counselling documented · Metformin started (if eGFR confirmed ≥45)

eGFR before metforminDESMOND mandatoryEye screening day 1DVLA counselling documented

3 months — treatment response

HbA1c response — has it improved? · Side effect review (GI → try SR formulation) · Lifestyle progress and DESMOND attendance · Intensify by phenotype if HbA1c is above the agreed target on dual therapy (and if the patient was started on metformin alone, add the SGLT2 inhibitor now \u2014 NG28 Feb 2026) · Motivational support

6 months — stability check

Repeat HbA1c if still adjusting therapy · BP and weight · Medication adherence check · Psychosocial wellbeing · DESMOND attended? · Diabetic distress screen (PHQ-9)

1yr

Annual review — mandatory NICE

HbA1c + eGFR + ACR + lipids + BP (both arms) · Foot exam (monofilament + pulses) · NDESP result review · PHQ-9 / diabetes distress · Medication review · Smoking + alcohol · Weight trend · DVLA status if on SU/insulin

Mandatory annuallyFoot + eyes + kidney

Rem

Remission criteria (if applicable)

HbA1c <48 sustained ≥3 months off glucose-lowering medication. Continue annual monitoring — relapse is common. Document remission status. Patient still needs eye screening, foot exam, BP, ACR monitoring.

7I — Monitoring targets and thresholds

Test	Timing	Action threshold
HbA1c	3-monthly until stable; 6-monthly then	>53 on metformin → add Step 2. >75 despite dual → triple or specialist.
eGFR + U&E	Annually (6-monthly if eGFR <60)	eGFR <45 → reduce metformin; <30 → stop. K⁺ >5.5 → review ACEi/ARB.
ACR	Annually	≥3 → start ACEi/ARB; ≥30 → intensify BP. ≥70 → nephrology referral considered.
Lipids	Annually (3m after statin change)	LDL >2.6 despite statin → uptitrate; check adherence.
BP	Every visit	≥140/90 on 2 occasions (or ≥130/80 with CKD/ACR≥70) → start/intensify (ACEi first-line in T2DM).
Weight / BMI	Every visit	Ongoing gain → revisit diet; consider SGLT2i or GLP-1 RA.
Foot exam	Annually (6-monthly if high-risk)	Loss of sensation or absent pulses → podiatry + MDT foot clinic.
Eye screening (NDESP)	Annually	Any retinopathy → ophthalmology; proliferative → urgent.
Vitamin B12	Annually after 4 years metformin	Low B12 → supplement; consider neuropathy if borderline.

Key targets to know

HbA1c: <48 general · <53 on SU/insulin · Individualise in frailty

BP: <140/90 in T2DM; <130/80 if CKD or ACR ≥70

LDL: <2.6 mmol/L (or ≥40% reduction from baseline)

Remission: HbA1c <48 sustained ≥3 months OFF all glucose-lowering medication

999: DKA/HHS · FAST · Silent MI · Euglycaemic DKA on SGLT2i · Active foot sepsis

Safeguarding: Capacity for self-management · Falls risk on SU/insulin · Food security · HGV driving duty of care

Urgent: HbA1c >86 · LADA features · Rapid oral failure · Active foot ulcer · New retinopathy

DVLA: Metformin/SGLT2i/DPP-4i: no notification. SU/insulin: notify; monitoring rules; annual review

7J — Safety-netting: exact phrases for every T2DM patient

⚠ Three scenario-specific phrases — use these verbatim

Why safety-netting is especially important in T2DM

DKA can occur in T2DM — especially on SGLT2i (euglycaemic); sick day rules prevent fatal delayed presentation

HHS carries 20% mortality — gradual onset; patients often present very late without prior warning

HGV drivers on hypoglycaemic agents: undocumented DVLA counselling = medico-legal liability if accident occurs

Metformin must be withheld in dehydration, contrast, and perioperative settings — verbal + written instruction needed

T2DM complications (retinopathy, nephropathy, neuropathy) can deteriorate silently between reviews — patients must know what to report

Injection site technique errors → lipohypertrophy → erratic insulin absorption → glycaemic instability

3 monthsHbA1c response · Side effects · Lifestyle check · Add Step 2 if HbA1c >53

6 monthsStability check · DESMOND attendance · Psychosocial wellbeing · Adherence

AnnualFull review: HbA1c + eGFR + ACR + lipids + BP + foot + eyes + PHQ-9 + medication review

📋 SCA Consultation Scorecard — self-assess your consultation

🏥

Clinic Quick Reference

T2DM — Diagnostic Pathway & Management Summary

NICE NG28 · Numbers · Drug decision tree · Safety netting · Monitoring

▼expand

🔬 1 — Diagnostic Pathway & Triage Algorithm

Raised glucose / HbA1c ≥42 mmol/mol identified

↓

🚨 Emergency — 999

DKA: vomiting + ketones ≥3 + glucose >11
HHS: glucose >30 + confusion + dehydration
FAST positive symptoms
Euglycaemic DKA on SGLT2i
Active foot sepsis / gangrene

999 immediately

⚠ Urgent — same week

HbA1c >86 + osmotic symptoms
LADA features (slim, autoimmune, rapid failure)
New foot ulcer / Charcot joint
Rapid oral agent failure (<6 months)
Proliferative retinopathy on NDESP

Urgent face-to-face

✓ Routine — planned

HbA1c 48–85, asymptomatic: 2nd test to confirm
HbA1c 42–47: pre-diabetes → NHS DPP
Known T2DM stable: annual review pathway
Intensification needed: planned structured review

NICE NG28 pathway

🔢 2 — Key Numbers to Know

HbA1c thresholds

<42

Normal

42–47

Pre-diabetes

≥48

T2DM (×2 if asymp)

Target — general	<48 mmol/mol
Target on SU/insulin	<53 mmol/mol
Dual therapy from outset	>86 mmol/mol
Remission (DiRECT ≥15 kg)	<48 ≥3m off all meds

Other key targets

BP target (T2DM)	<140/90 (<130/80 if CKD/ACR≥70)
LDL target	<2.6 mmol/L
eGFR: reduce metformin	<45 mL/min
eGFR: stop metformin	<30 mL/min
ACR: start ACEi/ARB	≥3 mg/mmol
DVLA (metformin/SGLT2i)	No notification

💊 3 — Medication Decision & Choice

Step	Drug	Condition	DVLA Group 2
Step 1	MR metformin + SGLT2i (dual)	All T2DM needing medication · No hypo · eGFR ≥30 · SGLT2i unless frailty risk	No notification
Step 2A	SGLT2i	CVD / HF / CKD / obesity · eGFR ≥45	No notification
Step 2B	GLP-1 RA	BMI ≥35 / CVD / high HbA1c · SC injection	No notification
Step 2C	DPP-4i	SGLT2i/GLP-1 RA not suitable · Weight neutral	No notification
Step 2D	SU (Gliclazide MR)	Other Step 2 not suitable · Hypo risk · Weight gain	Notify + monitor
Step 4+	Insulin	HbA1c >75 on triple · Rapid beta-cell failure	Notify + annual review

⛔ Metformin + eGFR <30 = stop · ⛔ SGLT2i + unwell = euglycaemic DKA risk (hold) · ⛔ SU + HGV = DVLA notification mandatory · ⛔ GLP-1 RA + pancreatitis history = contraindicated

⚠ 4 — Safety Netting & Follow-Up

Follow-up schedule

Diagnosis: eGFR + U&E + ACR + lipids + LFTs + TSH + ECG · foot exam · NDESP referral · DESMOND referral · DVLA counselling documented · Metformin start (eGFR confirmed ≥30)

3 months: HbA1c response · Side effects (GI → SR) · Lifestyle progress · Add Step 2 if HbA1c >53

6 months: Stability · BP + weight · Adherence · PHQ-9

1yr

Annual: HbA1c + eGFR + ACR + lipids + BP · Foot exam · NDESP result · PHQ-9 · Medication review · DVLA status if on SU/insulin

📌 Group 2 DVLA: Metformin/SGLT2i/DPP-4i = no notification. SU = notify + monitoring. Insulin = notify + annual review.

🔬 5 — Monitoring Targets

Test	Timing	Action threshold
HbA1c	3-monthly until stable; 6-monthly	>53 on metformin → add Step 2. >75 on dual → triple/specialist.
eGFR + U&E	Annually (6-monthly if <60)	<45 → reduce metformin. <30 → stop. K⁺ >5.5 → review ACEi/ARB.
ACR	Annually	≥3 → ACEi/ARB. ≥30 → intensify BP. ≥70 → nephrology.
BP	Every visit	≥140/90 on ×2 (or ≥130/80 if CKD/ACR≥70) → start/intensify (ACEi first-line).
Foot exam	Annually (6-monthly if high-risk)	Loss of sensation/absent pulses → podiatry + MDT.
Eye screening	Annually (NDESP)	Background retinopathy → ophthalmology. Proliferative → urgent.
Lipids	Annually	LDL >2.6 → uptitrate statin. Age >40 T2DM (or QRISK3 ≥10%) → atorvastatin 20mg.
Vitamin B12	Annually after 4 yrs metformin	Low → supplement. Neuropathy → check regardless of duration.

999: DKA · HHS · FAST · Euglycaemic DKA on SGLT2i · Foot sepsis · Sudden vision loss

Safeguarding: Capacity · Falls risk (SU/insulin) · Food security · HGV duty-of-care documentation

🛡️ 6 — Complication Prevention

Eyes — prevent blindness

NDESP at diagnosis + annually. Tight HbA1c + BP <130/80 reduces progression 25–35%. Background retinopathy → ophthalmology. Proliferative → urgent.

Kidneys — prevent dialysis

ACR annually. ACEi/ARB if ACR ≥3. SGLT2i slows CKD progression. eGFR-guided prescribing. Tight BP + HbA1c.

Feet — prevent amputation

Annual foot exam (monofilament + pulses). High-risk → podiatry. Any ulcer → MDT same day. 50% of UK amputations in T2DM patients.

🎓

SCA Exam Quick Reference

SCA Consultation Blueprint

Tasks · Relating to Others · Global Skills · RAG guide

▼expand

🕐 12-Minute Consultation Flow

0–2 min

Open & ICE

"I can see from your blood test that your HbA1c came back at 56 — before I explain what that means, tell me what has been going through your mind since that letter arrived."

"You mentioned your wife uses insulin — what does that bring up for you?"

"What were you most hoping we could sort out today?"

Relating to OthersGlobal Skills

✗ Not acknowledging HbA1c from notes · Asking for info already documented · Going straight to prescribing · Missing injection fear + licence

2–5 min

Safety Screen

"Are you feeling well — any vomiting, confusion, or severe dehydration?"

Red flags aloud: DKA/HHS · LADA (slim + autoimmune) · Active foot problem · Visual change

Occupation: HGV — ask directly. Family complications — uncle's eyes?

TasksGlobal Skills

✗ No red flag screen · Not asking occupation · Not considering LADA · Overrunning data gathering

5–7 min

Context & Risk

eGFR (needed before metformin). Diet — HGV meal reality. CVD/BP/smoking.

Uncle's blindness: "Has anyone in your family had complications from diabetes — to their eyes or feet?"

Diabetes distress screen. Wife's impact on David's understanding.

TasksRelating to Others

✗ No eGFR before prescribing · Generic dietary advice · Uncle collected not used in plan

7–10 min

Explain & Address ICE

"Type 2 is completely different from what your wife has. Injections are not part of the plan today."

"With metformin, your licence does not change — it cannot cause low blood sugar on its own."

"Your uncle's blindness — we are setting up annual eye screening today so we catch any change early."

TasksRelating to Others

✗ Wrong DVLA info (saying licence lost) · Not distinguishing T1/T2 · Jargon · Uncle's blindness not used

10–12 min

Plan & Close

"If you are vomiting and cannot keep fluids down — stop the metformin and go to A&E. Here is your sick day rules card."

One specific lifestyle change agreed · DESMOND referral · NDESP referral · HbA1c in 3 months · "Is there anything else?"

TasksRelating to OthersGlobal Skills

✗ No DESMOND · No eye screening · No sick day rules · Vague follow-up · No closing question

🔴🟠🟢 RAG — All 3 Domains

Tasks

🟢

eGFR confirmed before metformin · DESMOND referred · NDESP booked · Foot exam done · Sick day rules given written · DVLA accurate (metformin = no notification) · LADA considered · 3-month HbA1c named · Uncle used in plan

🟠

eGFR mentioned not confirmed · DESMOND not actively referred · Sick day rules verbal only · DVLA partially correct · Foot exam incomplete · Follow-up vague

🔴

Metformin without eGFR · No DESMOND · No eye screening · Wrong DVLA info · No safety netting · No foot exam

Relating to Others

🟢

T1 vs T2 explicit · Injection fear addressed unprompted · DVLA accurate + specific · Uncle named in prevention · Occupational diet explored · Chunk-and-check · "Anything else?"

🟠

Injection fear partial · DVLA incomplete · Uncle collected not used · Dietary advice generic · No chunk-and-check

🔴

Straight to management · Wrong DVLA catastrophises · Injection fear ignored · Jargon · No shared decision-making

Global Skills

🟢

Notes used first · Open Q · Data gathering by 6–7 min · Lay language · Expectation before management · Responsive to cues · Structured

🟠

Some jargon · Overruns · Misses occupational context · Expectation addressed after plan

🔴

Notes not used · Jargon throughout · Data gathering incomplete · No structure · Cues ignored

💬 Key Phrases

💭 Ideas

"What does the word diabetes mean to you? Was it your wife's situation that came to mind?"

😟 Concerns — all three

"I want to address the three things you mentioned — the injections, your licence, and your uncle. Let me go through each one specifically."

🎯 Expectation first

"Before I go through the plan — can I address the injection question and the licence question right now, because that changes how the whole conversation feels."

🗣️ T1 vs T2

"Type 2 is completely different from what your wife has. Her pancreas stopped working — that is autoimmune, Type 1. Yours still works. Injections are not part of the plan today."

🚛 DVLA accurate

"Metformin cannot cause your blood sugar to drop too low on its own — so the DVLA rules do not apply. Your HGV licence is not at risk at this stage."

✅ Uncle + close

"We are setting up annual eye screening today so we catch any change before it causes problems. HbA1c in 3 months. Sick day rules card. Anything else?"

🚫 9 Danger Zones

✗

Telling David he will lose his HGV licence on metformin
→ Metformin-only: NO DVLA notification. This catastrophises needlessly and destroys engagement.

✗

Not distinguishing Type 1 from Type 2
→ David thinks T2DM = his wife's T1DM. Correct this explicitly, early, by name.

✗

Prescribing metformin without confirming eGFR
→ eGFR <30 = contraindication (lactic acidosis). Always confirm first.

✗

Not referring to DESMOND
→ NICE-mandated. Omission = Tasks deduction.

✗

Not booking NDESP at diagnosis
→ Mandatory. Uncle's blindness makes this omission especially significant.

✗

Collecting uncle's blindness but not using it
→ "We can prevent what happened to your uncle" = highest-quality shared decision-making.

✗

No foot exam at first T2DM presentation
→ NICE mandates this. Neuropathy may already be present.

✗

Generic dietary advice without exploring HGV reality
→ Standard advice fails lorry drivers. Explore motorway meal reality first.

✗

No sick day rules (verbal + written)
→ Metformin in DKA = lactic acidosis. SGLT2i when unwell = euglycaemic DKA. Written card mandatory.

💊 Drug Quick-Pick

First-line — all T2DM

→

MR metformin + SGLT2i

Dual (NG28 2026). eGFR ≥30. No DVLA.

CVD / HF / CKD

→

SGLT2i

Empa / Dapa. No DVLA.

BMI ≥35 / high HbA1c

→

GLP-1 RA

Semaglutide. No DVLA.

HGV-safe / hypo risk

→

DPP-4i

Sitagliptin. No DVLA.

Avoid HGV if possible

→

SU (Gliclazide)

Hypo risk. Notify DVLA.

Step 4+ / specialist

→

Insulin

Notify DVLA. Annual review.

⛔ Metformin + eGFR <30 = STOP · ⛔ SGLT2i + unwell = euglycaemic DKA · ⛔ SU + HGV = DVLA mandatory · ⛔ GLP-1 RA + pancreatitis = CI

Type 2 Diabetes · GP Clinical Reasoning Framework · NICE NG28 (2022) · NICE NG17 · NICE CKS 2025 · DiRECT Trial · EMPA-REG OUTCOME · LEADER · SUSTAIN · UKPDS

Includes: Clinical stem · Open Q first · ICE (injection fear + HGV licence + uncle blindness) · Safeguarding · DVLA Group 2 rules · T1 vs T2 distinction · Foot exam mandatory · eGFR before metformin · DESMOND + NDESP · Drug selector tool · Sick day rules · SCA RAG checkpoints · Dual collapsible summaries · SCA Scorecard /33

Teaching clinicians why each step matters — not just what to do · Always consult current BNF/SPC/NICE guidelines · Clinical judgement takes precedence over any framework